Brief: Argenx Announces Approval Of VYVDURA In Japan
27/12/2024 06:06
Dec 27 (Reuters) - argenx SE ARGX.BR :
* ARGENX ANNOUNCES APPROVAL OF VYVDURA (EFGARTIGIMOD ALFA
AND
HYALURONIDASE-QVFC) IN JAPAN FOR ADULTS WITH CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Source text: ID:nGNE4KvJXK
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles